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Differentiation status influences the prognosis for localized prostate cancer. In this issue of Cancer Cell, Mak
and coworkers describe a signaling pathway involving estrogen receptor b (ERb) that governs whether
prostate carcinoma cells maintain an epithelial phenotype or undergo epithelial-mesenchymal transition,
suggesting that ERb would have prognostic or therapeutic value.Prostate cancer is the most common
cancer in men and the second leading
cause of cancer death in men. Charles
Huggins received the Nobel Prize in 1966
for the demonstration thatprostatecancers
respond to the administration of estrogen
or withdrawal of androgens. Unfortunately,
inhibition of androgen function, with or
without cytotoxic chemotherapy, is pallia-
tive, but not curative. It remains the main-
stay of treatment for metastatic prostate
cancer, however, because no new, vali-
dated, molecular targets have emerged
for this disease in the past 50 years.
Early-stage prostate cancer, in contrast
to disseminated disease, is often cured by
surgery or radiation. This knowledge has
motivated aggressive screening pro-
grams centered on measuring circulating
prostate specific antigen (PSA). Although
this strategy has undoubtedly saved lives,
it has also assuredly led to the diagnosis
of indolent prostate cancers that would
never have become clinically manifest.
Indeed, the prevalence of occult prostate
cancers in autopsy series reaches as high
as 80% in men 80 years and older. This
potential overdiagnosis is important
because both surgery and radiation can
cause significant morbidities.
Traditional methods of predicting out-
comes after local therapy for prostate
cancer have focused on clinical and
pathologic features, including the clinical
stage of disease, pretreatment PSA (a
measure of tumor burden), and state of
tumor differentiation (Gleason score). As a
result of PSA screening, however, most
prostate cancers are both small and
organ-confined at diagnosis. This negates
the use of stage or volume as discrimina-
tory parameters to predict aggressive-
ness and the subsequent developmentof metastases. Importantly, this leaves
Gleason score as arguably the most im-
portant prognostic parameter in prostate
cancer. Gleason grade is a measure of
the degree of differentiation of prostate
tumor cells; the sum of the primary
(predominant) Gleason pattern and the
secondary pattern is the Gleason score
(scaled 5–10). Patients with a Gleason
score%6 almost invariably have a benign,
nonaggressive, clinical course, while
patients with a Gleason score >8 are at
high risk of recurrence and death. Unfortu-
nately, the vast majority of newly diag-
nosed prostate cancers have a Gleason
Score of 7, and it is not yet possible to
reliably predict their outcome. This is a sig-
nificant problem because approximately
30% of this subgroup will eventually
relapse (Andriole et al., 2009; Schroder
et al., 2009).
Estrogens, via the interaction with their
receptors, regulate the growth and devel-
opment of both the mammary gland
and the male reproductive system. The
molecular effects of estrogens on prostate
epithelium are still largely unknown even
though their antitumor properties have
been known since the time of Huggins.
Whereas estrogen receptor a (ERa) and
ERb share some structural and functional
properties, individual characteristics allow
them to have distinct biological functions.
While the DNA-binding domains of ERa
and ERb are highly conserved, their amino
termini, important for transactivation, are
not. Although both receptors bind the
natural ligand 17b estradiol with about
equal affinity, phytoestrogens, 3b-Adiol,
and some selective estrogen receptor
modulators bind preferentially to either
ERa or ERb (Dutertre and Smith, 2000).
Cellular localization also differs: whileCancer CelERa is expressed only in stromal cell
nuclei, ERb is expressed in basal cells of
normal prostatic acini, as well as in stromal
cells. In addition, tumor cells only express
ERb.
In this issue of Cancer Cell, Mak et al.
report that ERb, when activated by its
specific ligand 3b-Adiol, maintains an
epithelial phenotype and represses mes-
enchymal characteristics in prostate
cancer cells (Mak et al., 2010). The authors
show that ERb promotes the destabiliza-
tion of HIF-1a and downregulates the
canonical HIF target VEGF. Loss of ERb
therefore increases VEGF production,
which engages the VEGF receptor neuro-
pilin 1. This, in turn, leads to AKT activa-
tion, GSK3b inactivation, and ultimately,
the nuclear localization of SNAIL, which
promotes an epithelial to mesenchymal
transition (EMT) characterized by the loss
of E-cadherin and increased expression
of vimentin (Figure 1A). Importantly, the
authors show that high Gleason grade
(poorly differentiated) prostate carci-
nomas exhibit decreased ERb protein
levels and increased levels of HIF1a,
VEGF, and nuclear SNAIL, relative to
low-grade lesions. ERb mRNA levels
were previously found to be decreased in
hormone refractory prostate cancers,
supporting the contention that loss of
ERb correlates with disease progression
(Latil et al., 2001). On the other hand,
another recent study reported that high
ERbprotein levels associated with aworse
prognosis in prostate cancer patients
(Nanni et al., 2009). Clearly it will be impor-
tant to understand whether these discrep-
ancies are due to technical differences
between the studies.
Hypoxia and HIF activation have been
linked to the induction of EMT in otherl 17, April 13, 2010 ª2010 Elsevier Inc. 311
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Figure 1. Regulation of EMT by ERb
(A) Schematic linking ERb activation by its ligand, 3b-Adiol, to inhibition of HIF and suppression of an EMT.
(B) ERb is associated with differences in prostate cancer biology. Low-grade lesions typically have high
levels of ERb, while high-grade lesions have low levels of ERb. Treatment with an ERb agonist might,
however, promote differentiation of high-grade lesions. ERb status might also, in time, be shown to predict
outcomes for patients with intermediate-grade lesions and, hence, the need for additional therapy.
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tumor suppressor protein leads to consti-
tutive HIF activation, which induces renal
epithelial cells to undergo EMT as a result
of increased expression of transcriptional
repressors such as SIP1 and SNAIL
(Evans et al., 2007). EMT is believed to
increase tumor cell invasiveness and,
hence, metastasis, as well as chemother-
apeutic resistance. Moreover, cells in-
duced to undergo EMT in vitro upregulate
cell surface markers that are used to iden-
tify ‘‘cancer stem cells’’ (Mani et al., 2008).
The ability of HIF to induce EMT might
account for the frequent association of
intratumoral hypoxia and increased HIF
levels with a poor prognosis in diverse
cancers, including prostate cancer (Nanni
et al., 2009). A caveat, however, is that
aggressive tumors are more likely to
outgrow their blood supplies, which leads
to hypoxia and HIF stabilization. Hence,
it can be difficult to tease out cause
and effect from such descriptive clinical
studies.
Although it is tempting to invoke EMT
as a basis for aggressive cancer cell
behavior in vivo, this area remains contro-
versial. There is no convincing evidence
for conversion of epithelial cells into
mesenchymal cell lineages in human
tumors. In fact, the appearance of vimen-
tin staining in human tumors is taken as312 Cancer Cell 17, April 13, 2010 ª2010 Elsprima facie evidence that they are not of
epithelial origin. Furthermore, the biolog-
ical repertoire of carcinoma cells is suffi-
cient to account for biologic behavior,
such as development of metastases,
without invoking changes in cell lineage
(Tarin et al., 2005). Finally and importantly,
most tumors do not dedifferentiate as
they metastasize but retain the original
morphology and differentiation state
found in the primary tumor (Kramer
et al., 1981). Nonetheless, EMT in vitro
might be mirrored by more subtle state
changes in vivo that influence tumor cell
behavior. Moreover, such changes might
be highly plastic, responsive to microenvi-
ronmental changes such as hypoxia.
The study by Mak et al. raises the possi-
bility that measurement of ERb and EMT
markers will help to subclassify patients
with intermediate Gleason scores into
groups with a high or low risk of pro-
gression and, hence, guide therapeutic
decision making (Figure 1B). Second, it
suggests that drugs that modulate ERb,
or its downstream effectors such as HIF,
VEGF, neuropilin-1, and AKT, could favor-
ably alter the natural history of this dis-
ease. It also raises a number of questions.
For example, how do hypoxia and TGFb
lead to loss of ERb? One possibility,
based on the knowledge that hypoxia
and TGFb induce HIF, is that HIF andevier Inc.ERb are mutually inhibitory (Figure 1A).
A second question relates to how, mech-
anistically, ERb destabilizes HIF. Conceiv-
ably, ERb regulates one or more of the
prolyl hydroxylases that mark HIF for
destruction. In this regard, ERa transcrip-
tionally activates the PHD1 prolyl hydrox-
ylase, which has recently been linked to
the control of breast cancer proliferation
(Zhang et al., 2009). Finally, might some
of the salutary effects of high-dose
estrogen in prostate cancer be mediated
by ERb? Answers to questions such as
these might eventually add a new chapter
to the story begun by Huggins.ACKNOWLEDGMENTS
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